Skip to main content
  • FDA Approves EVOQUE as First Transcatheter Treatment for TR

    The EVOQUE Tricuspid Valve System is the first device to receive U.S. Food and Drug Administration (FDA) approval for transcatheter therapy of tricuspid regurgitation (TR), manufacturer Edwards Lifesciences announced Friday.

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details